Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A16AX14
|
| gptkbp:CASNumber |
620-67-7
|
| gptkbp:chemicalFormula |
C21H38O5
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
oral liquid
|
| gptkbp:genericName |
gptkb:triheptanoin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dojolvi
|
| gptkbp:indication |
treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Ultragenyx_Pharmaceutical
|
| gptkbp:mechanismOfAction |
provides medium odd-chain fatty acids as an energy source
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain fatigue |
| gptkbp:usedFor |
gptkb:long-chain_fatty_acid_oxidation_disorders
|
| gptkbp:bfsParent |
gptkb:Ultragenyx_Pharmaceutical
gptkb:Ultragenyx |
| gptkbp:bfsLayer |
7
|